SEC Comment Letter 0000000000-24-007001 to TriSalus Life Sciences, Inc. (TLSI)
TriSalus Life Sciences, Inc.
Date: June 18, 2024 · CIK: 0001826667 · Accession: 0000000000-24-007001
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-280197
Letter
United States securities and exchange commission logo June 18, 2024 Mary Szela Chief Executive Officer TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 Re:TriSalus Life Sciences, Inc. Registration Statement on Form S-1 Filed June 14, 2024 File No. 333-280197 Dear Mary Szela: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Conlon Danberg at 202-551-4466 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Carlos Ramirez, Esq.
Show Raw Text
United States securities and exchange commission logo
June 18, 2024
Mary Szela
Chief Executive Officer
TriSalus Life Sciences, Inc.
6272 W. 91st Ave.
Westminster, Colorado 80031
Re:TriSalus Life Sciences, Inc.
Registration Statement on Form S-1
Filed June 14, 2024
File No. 333-280197
Dear Mary Szela:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Conlon Danberg at 202-551-4466 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Carlos Ramirez, Esq.